Habibullah Aktaş1, Can Ergin2, Betül Demir3, Özlem Ekiz4. 1. Department of Dermatology, Education and Research Hospital, Karabük University, Karabük, Turkey. 2. Department of Dermatology, Dışkapı Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey drcanergin@hotmail.com. 3. Department of Dermatology, Fırat University Hospital, Elazığ, Turkey. 4. Department of Dermatology, Faculty of Medicine, Mustafa Kemal University, Hatay, Turkey.
Abstract
BACKGROUND: Plantar warts are typically resistant to treatment. In recent years, treatments have included administration of intralesional tuberculin; measles, mumps, rubella vaccine; and Candida albicans antigen immunotherapy. To the best of our knowledge, there are no reports of intralesional vitamin D administration for the treatment of warts. AIM: To evaluate the efficacy and safety of intralesional vitamin D treatment for plantar warts. METHODS: Twenty patients with single or multiple plantar warts were included in this study. Vitamin D(3) (0.2 mL, 7.5 mg/mL) was injected into the base of the warts after prilocaine (0.1 mL, 20 mg/mL) injection. A maximum of 5 warts were treated in 1 session, with at maximum 2 injections performed at 4-week intervals. RESULTS: In total, 16 of 20 patients (80%) showed complete resolution of warts, and 1 patient showed partial resolution. Three patients failed to show any response. No recurrence or serious adverse effects were observed. CONCLUSION: Intralesional vitamin D(3) may be an effective treatment option for warts.
BACKGROUND: Plantar warts are typically resistant to treatment. In recent years, treatments have included administration of intralesional tuberculin; measles, mumps, rubella vaccine; and Candida albicans antigen immunotherapy. To the best of our knowledge, there are no reports of intralesional vitamin D administration for the treatment of warts. AIM: To evaluate the efficacy and safety of intralesional vitamin D treatment for plantar warts. METHODS: Twenty patients with single or multiple plantar warts were included in this study. Vitamin D(3) (0.2 mL, 7.5 mg/mL) was injected into the base of the warts after prilocaine (0.1 mL, 20 mg/mL) injection. A maximum of 5 warts were treated in 1 session, with at maximum 2 injections performed at 4-week intervals. RESULTS: In total, 16 of 20 patients (80%) showed complete resolution of warts, and 1 patient showed partial resolution. Three patients failed to show any response. No recurrence or serious adverse effects were observed. CONCLUSION: Intralesional vitamin D(3) may be an effective treatment option for warts.